

CLAIMS

I claim:

- Sub 26
1. A vaccine comprising:
a pharmaceutical composition comprising isolated and purified cell surface adhesin protein obtained from a *Candida* strain.
 2. The vaccine of Claim 1, wherein the cell surface adhesin protein is *Candida albicans* ALS1 adhesin protein (Als1p).
 3. The vaccine of Claim 2, wherein the protein is a fragment encompassing the N-terminus of Als1p and containing the adhesin binding site.
 4. The vaccine of Claim 1, wherein said cell surface adhesin protein is derived from a Candidal strain selected from the group consisting of *Candida krusei*, *Candida tropicalis*, and *Candida parapsilosis*.
 5. A method for treatment and prevention of disseminated candidiasis, comprising:
administering a vaccine comprised of a pharmaceutically effective amount of an ALS1 adhesin protein of *Candida albicans* in an amount elicit to an immune response.
 6. The method of Claim 5, wherein said step of administering vaccine comprises the step of using active immunization through administration of the *Candida albicans* ALS1 gene product.
 7. The method of Claim 5, wherein said step of administering vaccine comprises passive immunization through administration of antiserum to ALS1 gene product.

add B^8

[illegible]